<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-12-12 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-12-12/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-12-12"><meta property="og:description" content="ğŸ“… Daily Report - 2025-12-12 ä»Šæ—¥ç­›é€‰å‡º 61 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-12-12T00:00:00+00:00"><meta property="article:modified_time" content="2025-12-12T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week502025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-12-12"><meta itemprop=description content="ğŸ“… Daily Report - 2025-12-12 ä»Šæ—¥ç­›é€‰å‡º 61 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-12-12T00:00:00+00:00"><meta itemprop=dateModified content="2025-12-12T00:00:00+00:00"><meta itemprop=wordCount content="2299"><meta itemprop=keywords content="Research,Daily,Week502025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-12-12"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-12-12 ä»Šæ—¥ç­›é€‰å‡º 61 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-12</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-12-12T00:00:00Z>2025-12-12</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-12-12>ğŸ“… Daily Report - 2025-12-12</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>61</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
é¦–æ¬¡æ­ç¤ºè°·æ°¨é…°èƒºåˆæˆé…¶ï¼ˆGSï¼‰åœ¨Î²-cateninçªå˜è‚ç™Œä¸­ç¼ºå¤±å¦‚ä½•é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œé©±åŠ¨å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒé€‚åº”ï¼Œä¸ºè‚¿ç˜¤å…ç–«æ²»ç–—æä¾›æ–°é¶ç‚¹ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚¿ç˜¤ä»£è°¢é‡å¡‘ä¸å…ç–«é€ƒé€¸æœºåˆ¶ï¼ˆè‚ç™Œã€è†€èƒ±ç™Œã€éå°ç»†èƒè‚ºç™Œã€ä¹³è…ºç™Œï¼‰</li><li>ç»†èƒä¿¡å·é€šè·¯è°ƒæ§ä¸ç–¾ç—…è¿›å±•ï¼ˆWntã€EGFR-TKIã€é›„æ¿€ç´ å—ä½“ã€çƒ­ä¼‘å…‹é€šè·¯ï¼‰</li><li>è‚ é“èŒç¾¤ä»£è°¢äº§ç‰©ä¸è‚ é“ç¨³æ€ç»´æŒ</li><li>ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼ˆC9orf72çªå˜ã€Tauç—…ç†ï¼‰çš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆç³–å°¿ç—…å† è„‰å¾®å¾ªç¯ã€åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–è¡€æ “ï¼‰ç ”ç©¶ä¸­çš„åº”ç”¨ï¼Œæ­ç¤ºåŒºåŸŸå¼‚è´¨æ€§ã€‚</li><li>ç»“åˆå•ç»†èƒRNAæµ‹åºå’Œå…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åºï¼Œæ·±å…¥è§£æç»†èƒå¼‚è´¨æ€§ã€åŸºå› ç»„ç”²åŸºåŒ–ä¸å‘è‚²ã€ç–¾ç—…çš„å…³è”ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
æ–°å‹MUTE-SeqæŠ€æœ¯æœ‰æœ›å®ç°å¯¹ä½é¢‘ç™Œç—‡çªå˜çš„è¶…çµæ•æ£€æµ‹ï¼›è‚¥èƒ–è¢«è¯å®èƒ½æ˜¾è‘—åŠ é€Ÿé˜¿å°”èŒ¨æµ·é»˜ç—…çš„è¿›å±•ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>ç™Œç—‡çªå˜æ£€æµ‹ï¼šé€šè¿‡å¯Œé›†ç¨€æœ‰çªå˜ï¼Œæé«˜æ¶²ä½“æ´»æ£€çš„çµæ•åº¦ã€‚</li><li>é˜¿å°”èŒ¨æµ·é»˜ç—…ç ”ç©¶ï¼šæ­ç¤ºè‚¥èƒ–å¯¹ç–¾ç—…è¿›å±•çš„åŠ é€Ÿä½œç”¨ã€‚</li><li>ç™Œç—‡æ²»ç–—æŠµæŠ—æœºåˆ¶ï¼šå‘ç°ç™Œç»†èƒåˆ©ç”¨DNAé™è§£é…¶çš„ç”Ÿå­˜ç­–ç•¥ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>MUTE-Seqï¼šé€šè¿‡å»é™¤é‡ç”Ÿå‹DNAæ¥å¯Œé›†ç¨€æœ‰çªå˜ã€‚</li><li>æ—©æœŸç”Ÿç‰©æ ‡å¿—ç‰©æ£€æµ‹ï¼šåˆ©ç”¨è¡€æ¶²æ£€æµ‹å¿«é€Ÿè¯„ä¼°è‚¥èƒ–å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„å½±å“ã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (58æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE298611 Î²-cateninçªå˜å‹è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset1.Spatial.Transcriptomics]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolismã€spatialã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : OtherOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298611">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE300260 AMPKä¾èµ–çš„è¡¨è§‚é—ä¼ ä»£è°¢è°ƒæ§ä»‹å¯¼ç´«æª€èŠªåœ¨è‚ç»†èƒç™Œä¸­çš„æŠ—ç™Œä½œç”¨ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€carcinomaã€metabolismã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Cayla Boycott ; Megan Beetch ; Katarzyna Lubecka-Gajewska ; Benjamin S Ramsey ; Sandra Torregrosa-Allen ; Bennett D Elzey ; Abigail Cox ; Nadia Atallah Lanman ; Aline de Conti ; Min Li ; Mario Ferruzzi ; Igor Pogribny ; Barbara Stefanska (corresponding author)Series Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusScope: Disrupted metabolism, often implicated in hepatocellular carcinoma (HCC), is linked to aberrant epigenetic patterns. Dietary polyphenols, including pterostilbene (PTS), have been demonstrated to remodel epigenetic landscapes and restore metabolic homeostasis by regulating the activity of AMP-activated protein kinase (AMPK), a protein recently shown to orchestrate a diverse set of networks to epigenetically mediate transcription. We therefore explored the mechanistic involvement of AMPK in the epigenetic effects of PTS in HCC. Methods and Results: We incorporated PTS into a choline-deficient amino acid defined HCC-inducing diet (CDAA) in male Fisher-344 rats and found significant attenuation in HCC development compared to CDAA alone. Transcriptomics by RNA-sequencing revealed PTS-upregulated targets, that were enriched in key metabolic processes, including the folate (Aldh1l1), methionine (Bhmt) and sarcosine (Dmdgh) cycles. PTS-mediated gene upregulation was linked to lower levels of histone H3-methylation at lysine 27 (H3K27me3) at gene promoters. Mechanistic studies in HCC HepG2 cells revealed that AMPK inhibition abolished epigenetic gene activation in response to PTS, which was accompanied by diminished binding of H3K27me3-demethylase KDM6A at promoters of PTS-target genes. Conclusion: Our findings provide evidence for new disease vulnerabilities that arise from epigenetic/metabolic changes and constitute novel opportunities for preventative and therapeutic success in HCC.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300260">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE290189 SHMT2 modulates the transcriptome and metabolism profiles to promote the tumor phenotypes of bladder cancer HT-1376 cells</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€metabolismã€transcriptome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaobo Guo ; Gang LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBladder cancer (BLCA) is a common malignant tumor of the urinary system. The development and progression of BLCA are controlled by multiple regulatory molecules, which have not been widely investigated. In this study, we explored the functions and downstream targets of serine hydroxy methyltransferase 2 (SHMT2) by silencing its expression using small interference RNA (siSHMT2) in HT-1376 cells. Whole transcriptome and metabolism profiles were deeply analyzed to identify the molecular targets of SHMT2. We found that siSHMT2 significantly reduced the proliferation rate and altered the cell cycle stages of HT-1376 cells. Moreover, siSHMT2 can modulate the expression of hundreds of genes (DEGs), including 126 upregulated and 106 downregulated DEGs. We then found that the most significant DEGs were tightly associated with progression of cancers, including PTMA, HNRNPR, RAPH1, TRAF3IP1, CNBP, and PRR15. At the same time, the alternative splicing profile was also regulated by siSHMT2, including the skipped exon as the dominant AS types. Finally, we identified the differential metabolites (DMs), and found the metabolism profile was significantly regulated by siSHMT2. Besides the purine metabolism, we observed that valine, leucine and isoleucine biosynthesis and degradation, TCA cycle, and propanoate metabolism were among the top pathways of DMs. In summary, we highlight the important roles of SHMT2 in HT-1376 cells and identified its downstream molecular targets, which are associated with the development of BLCA and can be used as therapeutic targets of BLCA in future.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290189">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE298616 Î²-cateninçªå˜å‹è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº”</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298616">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE298614 Î²-cateninçªå˜è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset3.scRNAseq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298614">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE298613 Î²-cateninçªå˜è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset2.scRNAseq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298613">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE298111 GLMPé€šè¿‡æ¿€æ´»è‡ªå™¬å’ŒRhoAé€šè·¯ä¿ƒè¿›éå°ç»†èƒè‚ºç™Œçš„EGFR-TKIè€è¯æ€§</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Liang ; Jiali Xu ; Erbao Zhang ; Renhua GuoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHere, we report that the EGFR-TKI resistance mechanism is mediated by lysosome-related regulation. We established an osimertinib-resistant cell line, designated PC9OR, derived from the parental PC9 cells. The overexpression of glycosylated lysosomal membrane protein (GLMP) in PC9OR promotes resistance to Osimertinib. Mechanistically, GLMP could regulate the ubiquitination of RhoA and promote resistance by activating the epithelial-mesenchymal transition (EMT). Our findings provide a potential therapeutic strategy to overcome resistance to EGFR-TKIs.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298111">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>GSE296966 é›„æ¿€ç´ å—ä½“ä¿ƒè¿› ER çªå˜ä¹³è…ºç™Œä¸­çš„çº¿ç²’ä½“æ°§åŒ–ç£·é…¸åŒ–ã€è‚‰ç¢±ä»£è°¢å’Œå¯¹æ£•æ¦ˆé…¸è„‚æ¯’æ€§çš„æŠµæŠ—ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolismã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sessions Dane ; Spoelstra Nicole ; Caino Cecilia ; Yu Min ; Goodspeed Andrew ; Richer JenniferSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe effect of androgen receptor (AR) in ER+ breast cancer remains controversial. We find that AR promotes tumor cell growth, oxidative phosphorylation, and fatty acid oxidation under conditions mimicking long-term aromatase inhibition. AR also promotes expression of the mitochondrial and peroxisomal acylcarnitine synthesis enzyme CRAT. AR inhibition decreases CRAT expression and CRAT knockdown is sufficient to inhibit OXPHOS. AR inhibition does not elicit a broad anti-OXPHOS transcriptomic signature, but does affect the expression of a few key metabolic enzymes. AR antagonism also induces a metabolomic signature consistent with severe OXPHOS dysfunction. This work identifies AR as a regulator of CRAT and OXPHOS in ER+ breast cancer.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296966">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>GSE313152 ä¹³è…ºç™Œæ‚£è€…è‚ºè½¬ç§»ç¶å’Œæ­£å¸¸è‚ºç»„ç»‡çš„å•ç»†èƒ RNA æµ‹åºã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€sequencingã€single-cell</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : C E Caldon ; Leila EshraghiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generated slow-growing resistant cells that form small primary tumours but readily metastasize. Single-cell RNA sequencing (scRNAseq) revealed that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We found in clinical cohorts that P-Rex1 is high in ER+ breast cancer, including in late recurrent disease.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313152">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> â­ <strong>GSE255130 è‚ é“èŒç¾¤ä»£è°¢äº§ç‰©å²å“š-3-ä¹™é…¸é€šè¿‡è½¬å½•å› å­AHRç»´æŒè‚ é“ä¸Šçš®ç¨³æ€</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgutã€regex:gut(-?microbiome)?ã€regex:intestin(e|al)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Mengfan LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusThe incidence and prevalence of inflammatory bowel disease (IBD) is gradually increasing. A high-fat diet (HFD) is known to disrupt intestinal homeostasis and aggravate IBD, yet the underlying mechanisms remain largely undefined. Here, a positive correlation between dietary fat intake and disease severity in both IBD patients and HFD-fed mice is observed. HFD induces a significant decrease in indole-3-acetic acid (IAA) and lead to intestinal barrier damage. Furthermore, IAA supplementation enhances the intestinal mucin sulfation and effectively alleviates colitis. Mechanistically, IAA upregulates key molecules involved in mucin sulfation, including Papss2 and Slc35b3, the synthesis enzyme and the transferase of 3&rsquo;-phosphoadenosine-5&rsquo;-phosphosulfate (PAPS), via the Aryl Hydrocarbon Receptor (AHR). More importantly, AHR can directly bind to the transcription start site of Papss2. Oral administration of Lactobacillus reuteri, which can produce IAA, contributes to protecting against colitis and promoting mucin sulfation, while the modified L. reuteri strain lacking the iaaM gene (LactobacillusÎ”iaaM) and the ability to produce IAA fails to exhibit such effects. Overall, IAA enhances intestinal mucin sulfation through AHR, contributing to the protection of intestinal homeostasis.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255130">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 48 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨3æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4><p><strong>1.</strong> <strong>MUTE-Seqâ€”â€”ä¸€ç§æ£€æµ‹ä½é¢‘ç™Œç—‡çªå˜çš„è¶…çµæ•æ–¹æ³•</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šMUTE-Seq enriches rare cancer mutations by removing wild-type DNA, enabling highly sensitive detection that enhances liquid biopsy..</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/mute-seq-ultrasensitive-method-to-detect-low-frequency-cancer-mutations/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>è¡€æ¶²æ£€æµ‹æ˜¾ç¤ºï¼Œè‚¥èƒ–ä¼šè¿…é€ŸåŠ é€Ÿé˜¿å°”èŒ¨æµ·é»˜ç—…çš„å‘å±•è¿›ç¨‹ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šObesity accelerates the rise of Alzheimerâ€™s-related blood biomarkers far more rapidly than previously recognized. Long-term imaging and plasma data show that obese individuals experience much faster increases in proteins linked to neurodegeneration and amyloid buildup. Surprisingly, blood tests detected these changes earlier than PET scans. The results point to obesity as a major, modifiable contributor to Alzheimerâ€™s progression.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/12/251210092019.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>ç§‘å­¦å®¶æ­ç¤ºç™Œç—‡å¾—ä»¥åå¼¹çš„éšè—ç”Ÿå­˜ç§˜è¯€</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šScientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzymeâ€”normally seen in cell deathâ€”to survive treatment. Instead of dying, these â€œpersister cellsâ€ leverage this sublethal signal to regrow. Because the mechanism is non-genetic, it appears much earlier than typical resistance mutations. Targeting this enzyme could help stop tumors from returning.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/12/251210092022.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>cancer</td><td>9</td></tr><tr><td>immune</td><td>8</td></tr><tr><td>metabolism</td><td>8</td></tr><tr><td>sequencing</td><td>7</td></tr><tr><td>RNA-seq</td><td>6</td></tr><tr><td>carcinoma</td><td>6</td></tr><tr><td>spatial</td><td>6</td></tr><tr><td>single-cell</td><td>5</td></tr><tr><td>genome</td><td>5</td></tr><tr><td>macrophage</td><td>5</td></tr><tr><td>tumor</td><td>4</td></tr><tr><td>transcriptome</td><td>4</td></tr><tr><td>scRNA</td><td>3</td></tr><tr><td>epigenetic</td><td>2</td></tr><tr><td>resistance</td><td>2</td></tr><tr><td>pathway</td><td>2</td></tr><tr><td>transcriptomics</td><td>1</td></tr><tr><td>T cell</td><td>1</td></tr><tr><td>Visium</td><td>1</td></tr><tr><td>aging</td><td>1</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (48æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301532">GSE301532 C9orf72çªå˜ä½“å’ŒåŒæºå¯¹ç…§äººiPSCè¡ç”Ÿå°èƒ¶è´¨ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290095">GSE290095 2 å‹ç³–å°¿ç—…å† çŠ¶åŠ¨è„‰å¾®å¾ªç¯çš„ç©ºé—´è½¬å½•ç»„åˆ†ææ­ç¤ºäº†å¿ƒè„ä¸åŒåŒºåŸŸçš„å¼‚è´¨æ€§ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290094">GSE290094 2 å‹ç³–å°¿ç—…å† çŠ¶åŠ¨è„‰å¾®å¾ªç¯çš„ç©ºé—´è½¬å½•ç»„åˆ†ææ­ç¤ºäº†å¿ƒè„ä¸åŒåŒºåŸŸçš„å¼‚è´¨æ€§ [Visium]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285383">GSE285383 CCL5 é€šè¿‡è°ƒèŠ‚è¡€å°æ¿é©±åŠ¨çš„ M2 å·¨å™¬ç»†èƒæåŒ–ä¿ƒè¿›è¡€ç®¡ç´§å¼ ç´  II è¯±å¯¼çš„å¿ƒè„é‡å¡‘</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283015">GSE283015 Spatial immune landscape of large artery atherosclerotic and cardioembolic thrombus retrieved from mechanical thrombectomy</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276026">GSE276026 RNAæµ‹åºç ”ç©¶å‰åˆ—è…ºç™Œç»†èƒä¸­FZD6åŸºå› æ•²ä½çš„æƒ…å†µ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312476">GSE312476 TRC-051384 æ¿€æ´»çƒ­ä¼‘å…‹é€šè·¯ä¿æŠ¤èºæ—‹ç¥ç»èŠ‚ç¥ç»å…ƒå…å—å™ªå£°å¼•èµ·çš„å¬åŠ›æŸå¤± [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174112">GSE174112 å•ç»†èƒè½¬å½•ç»„æ­ç¤ºäº†å“ºä¹³ä»”çŒªå’Œæ—©æœŸæ–­å¥¶ä»”çŒªå›è‚ çš„å¼‚è´¨æ€§å’Œä¸åŒçŠ¶æ€</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE165094">GSE165094 æ¡ƒæœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116645">GSE116645 å…¨åŸºå› ç»„DNAç”²åŸºåŒ–ä»‹å¯¼å¯å˜å‰ªæ¥è½¬å½•æœ¬</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109189">GSE109189 æ¢¨æœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109188">GSE109188 è‹¹æœæœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313098">GSE313098 æ—¶é—´åºåˆ— RNA-seq åˆ†ææ­ç¤ºäº†æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—… (CLL) è‡ªä½“å’Œå•åŸ¹å…»ä½“å¤–æ¨¡å‹ä¸­åŠ¨æ€çš„è½¬å½•ååº”å’Œç›¸äº’ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310345">GSE310345 è·¨ç‰©ç§å•ç»†èƒåˆ†ææ­ç¤ºçº¿ç²’ä½“åŠŸèƒ½éšœç¢çš„æ€§åˆ«å·®å¼‚æ˜¯ Tau ç—…ç†çš„ä¿å®ˆç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307293">GSE307293 å²©è—»ç³–åŸºè½¬ç§»é…¶ 8 è¡ç”Ÿçš„ç¯çŠ¶ RNA é€šè¿‡ ENO1-TNF ä¿¡å·é€šè·¯é©±åŠ¨å·¨å™¬ç»†èƒ M2 æåŒ–ï¼Œä»è€Œä¿ƒè¿›è‚ºç™Œè¿›å±•</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305935">GSE305935 æ¾³å¤§åˆ©äºšæµ·æ¹¾æˆ˜äº‰è€å…µçš„å…ç–«è½¬å½•ç»„å˜åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305134">GSE305134 RORB åœ¨ç¥ç»æ¯ç»†èƒç˜¤ç»†èƒä¸­çš„å…¨åŸºå› ç»„å ä½æƒ…å†µã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302840">GSE302840 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„ä¸€ä¸ªè½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302839">GSE302839 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„è½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ [è›‹ç™½è´¨]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302749">GSE302749 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„è½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ [è½¬å½•æœ¬]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299344">GSE299344 PARP å’Œ CLK/DYRK æŠ‘åˆ¶åœ¨è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§ç™Œä¸­çš„ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297829">GSE297829 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºäº†æ¥å—é€æ 3 å¹´æ‚£è€…è…¹è†œå¾®ç¯å¢ƒçš„åŠ¨æ€å˜åŒ–ï¼Œå¹¶ä¸ºè…¹è†œçº¤ç»´åŒ–æä¾›äº†æ–°çš„è§è§£ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296196">GSE296196 SIRPGä»¥CD47éä¾èµ–æ€§æ–¹å¼å¢å¼ºæ´»åŒ–è¯±å¯¼çš„Tç»†èƒå¢æ®–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293768">GSE293768 VTC3 å’Œ VTC2 å¯¹æ‹Ÿå—èŠ¥å…‰ç…§ä¸‹è½¬å½•ç»„çš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287861">GSE287861 ç ”ç©¶å‘ç°ï¼Œå…³èŠ‚è½¯éª¨ä¸­ GATA4 æ°´å¹³çš„è¡°è€ç›¸å…³æ€§å‡é«˜ä¸è½¯éª¨ç»†èƒå†ç”Ÿèƒ½åŠ›å—æŸå’Œéª¨å…³èŠ‚ç‚æœ‰å…³ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278347">GSE278347 CEBPB drives endothelial pathological phenotype and promotes atherosclerosis by directly upregulating TGFBR1 expression [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278346">GSE278346 CEBPB é€šè¿‡ç›´æ¥ä¸Šè°ƒ TGFBR1 è¡¨è¾¾é©±åŠ¨å†…çš®ç—…ç†è¡¨å‹å¹¶ä¿ƒè¿›åŠ¨è„‰ç²¥æ ·ç¡¬åŒ– [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313261">GSE313261 å°é¼ è„¾è„ä¸­IL-33ã€IL-25ã€IL-13ã€TSLPã€IL-4å’ŒIL-9è¿‡è¡¨è¾¾çš„å…¨å±€è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313259">GSE313259 Apoe3 é€šè¿‡ Lrp4 å¢å¼ºä¹™é…°èƒ†ç¢±å—ä½“èšé›†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313176">GSE313176 MÃ¼llerç»†èƒè°·æ°¨é…°èƒºä»£è°¢å°†ç³–å°¿ç—…è§†ç½‘è†œç—…å˜ä¸­çš„å…‰æ„Ÿå—å™¨å’Œå†…çš®æŸä¼¤è”ç³»èµ·æ¥</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313146">GSE313146 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸æœ‰å…³ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313145">GSE313145 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸ç›¸å…³ [PCGA_miRNA_BX]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313144">GSE313144 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸ç›¸å…³ [PCGA_miRNA_BR]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313043">GSE313043 å•ç»†èƒè½¬å½•ç»„åˆ†æè¡¨æ˜ï¼Œè„‘å‡ºè¡€æœŸé—´æ¥å— BAF312 æ²»ç–—çš„æ‚£è€… TNF ä¿¡å·ä¼ å¯¼é™ä½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291568">GSE291568 å«SETç»“æ„åŸŸçš„è›‹ç™½è´¨å’ŒHCF-1ç»´æŒè·¨ä»£è¡¨è§‚é—ä¼ è®°å¿†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291081">GSE291081 Ly6G+Nur77+è¡€ç®¡å‘¨å›´å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289548">GSE289548 Ly6G+Nur77+å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311370">GSE311370 å°é¼ è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„å®Œæ•´ç©ºé—´å›¾è°±æ­ç¤ºäº†å¯†åº¦å’ŒåŸºå› è¡¨è¾¾ç‰¹åŒ– [En face Retina]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311369">GSE311369 å°é¼ è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„å®Œæ•´ç©ºé—´å›¾è°±æ­ç¤ºäº†å¯†åº¦å’ŒåŸºå› è¡¨è¾¾ç‰¹åŒ– [RGC_CrossSection]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305119">GSE305119 Ly6G+Nur77+å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281797">GSE281797 è‚¥èƒ–ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³è„‚è‚ªè‚æ‚£è€…è‚è„æ´»æ£€çš„è½¬å½•ç»„å­¦ç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310742">GSE310742 FABP4 æ˜¯å¿ƒè¡€ç®¡ç–¾ç—…é¢„åä¸è‰¯çš„æ ‡å¿—ç‰©ï¼Œå®ƒèƒ½è¯±å¯¼ä¸­æ€§ç²’ç»†èƒäº§ç”Ÿä¿ƒåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–çš„è¡¨å‹ï¼Œè€Œè¿™ç§è¡¨å‹å¯è¢«ç´¢ç›é²è‚½è°ƒèŠ‚ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291990">GSE291990 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ€§æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–æ€§æŸ“è‰²è´¨åŒºå®¤åŒ– [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291987">GSE291987 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–çš„æŸ“è‰²è´¨åŒºå®¤åŒ– [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291983">GSE291983 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–çš„æŸ“è‰²è´¨åŒºå®¤åŒ– [Hi-C]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284076">GSE284076 tRNA ç‰‡æ®µçš„è½¬å½•åä¿®é¥°èµ‹äºˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­é«˜å¯†åº¦è„‚è›‹ç™½åŠŸèƒ½æ”¹å˜ [å° RNA æµ‹åº]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284071">GSE284071 tRNA ç‰‡æ®µçš„è½¬å½•åä¿®é¥°èµ‹äºˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­é«˜å¯†åº¦è„‚è›‹ç™½åŠŸèƒ½æ”¹å˜ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270833">GSE270833 æ ¸ç›¸åˆ†ç¦»é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-11 21:39</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week502025/ rel=tag>Week502025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-12-11/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-11</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-12-13/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-12-13</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-03-01/>ç§‘ç ”æ—¥æŠ¥ 2026-03-01</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-28/>ç§‘ç ”æ—¥æŠ¥ 2026-02-28</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-27/>ç§‘ç ”æ—¥æŠ¥ 2026-02-27</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-26/>ç§‘ç ”æ—¥æŠ¥ 2026-02-26</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-25/>ç§‘ç ”æ—¥æŠ¥ 2026-02-25</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (122)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (122)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week082026/ title=Week082026>Week082026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week092026/ title=Week092026>Week092026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>